SMMT.US Summit Therapeutics PLC

Healthcare Biotechnology USA Stocks
10.77 USD
Close of Nov 17, 2026
10.53 29.23
Market cap
USD 8.61B
P/E
-
P/B
20.03x
ROE
-144.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SMMT.US undervalued?

Graham number

The Graham number of Summit Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Summit Therapeutics PLC fundamental analysis

No fundamental analysis for Summit Therapeutics PLC yet.

Summit Therapeutics PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is i…

Full company profile